Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Queensland Health
Healthtrust
Federal Trade Commission
QuintilesIMS
Citi
Deloitte
Boehringer Ingelheim
UBS

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020838

« Back to Dashboard

NDA 020838 describes ATACAND, which is a drug marketed by Ani Pharms Inc and Astrazeneca and is included in two NDAs. It is available from six suppliers. Additional details are available on the ATACAND profile page.

The generic ingredient in ATACAND is candesartan cilexetil; hydrochlorothiazide. There are twenty-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.
Summary for 020838
Tradename:ATACAND
Applicant:Ani Pharms Inc
Ingredient:candesartan cilexetil
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020838
Suppliers and Packaging for NDA: 020838
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATACAND candesartan cilexetil TABLET;ORAL 020838 NDA AstraZeneca Pharmaceuticals LP 0186-0004 N 0186-0004-31
ATACAND candesartan cilexetil TABLET;ORAL 020838 NDA AstraZeneca Pharmaceuticals LP 0186-0008 N 0186-0008-31

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength4MG
Approval Date:Jun 4, 1998TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength8MG
Approval Date:Jun 4, 1998TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength16MG
Approval Date:Jun 4, 1998TE:ABRLD:Yes

Expired US Patents for NDA 020838

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chubb
UBS
Johnson and Johnson
Merck
Cerilliant
McKesson
Accenture
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot